TipRanks (Mon, 23-Feb 7:40 AM ET)
IRhythm outlines 2026 revenue target of $870M–$880M while expanding AI and MCT innovation
Seeking Alpha News (Fri, 20-Feb 12:35 PM ET)
Wells Fargo Keeps Their Buy Rating on Irhythm Technologies (IRTC)
TipRanks (Fri, 20-Feb 7:06 AM ET)
Needham Sticks to Their Buy Rating for Irhythm Technologies (IRTC)
TipRanks (Fri, 20-Feb 6:57 AM ET)
BTIG Sticks to Its Buy Rating for Irhythm Technologies (IRTC)
TipRanks (Fri, 20-Feb 6:36 AM ET)
Analysts’ Top Healthcare Picks: Insmed (INSM), Irhythm Technologies (IRTC)
TipRanks (Fri, 20-Feb 12:50 AM ET)
iRhythm Technologies GAAP EPS of $0.17 beats by $0.18, revenue of $208.9M beats by $6.29M
Seeking Alpha News (Thu, 19-Feb 4:31 PM ET)
iRhythm Holdings Announces Fourth Quarter and Full Year 2025 Financial Results
Globe Newswire (Thu, 19-Feb 4:05 PM ET)
Here are the major earnings after the close Thursday
Seeking Alpha News (Thu, 19-Feb 10:00 AM ET)
iRhythm Technologies Q4 2025 Earnings Preview
Seeking Alpha News (Wed, 18-Feb 5:35 PM ET)
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
Irhythm Holdings trades on the NASDAQ stock market under the symbol IRTC.
As of February 23, 2026, IRTC stock price declined to $144.43 with 460,702 million shares trading.
IRTC has a beta of 0.60, meaning it tends to be less sensitive to market movements. IRTC has a correlation of 0.06 to the broad based SPY ETF.
IRTC has a market cap of $4.65 billion. This is considered a Mid Cap stock.
Last quarter Irhythm Holdings reported $209 million in Revenue and $.29 earnings per share. This beat revenue expectation by $7 million and exceeded earnings estimates by $.25.
In the last 3 years, IRTC traded as high as $212.00 and as low as $55.92.
The top ETF exchange traded funds that IRTC belongs to (by Net Assets): VTI, IWM, VB, VBK, VXF.
IRTC has outperformed the market in the last year with a return of +28.2%, while the SPY ETF gained +13.2%. However, in the most recent history, IRTC shares have underperformed the stock market with its stock returning -14.9% in the last 3 month period and -1.4% for the last 2 week period, while SPY has returned +5.1% and -1.0%, respectively.
IRTC support price is $146.18 and resistance is $155.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IRTC shares will trade within this expected range on the day.